Option FanaticOptions, stock, futures, and system trading, backtesting, money management, and much more!

AXTA Stock Study (8-21-24)

I recently did a stock study on Axalta Coating Systems Ltd. (AXTA) with a closing price of $34.33.

M* writes:

     > Axalta Coating Systems Ltd is a manufacturer, marketer and
     > distributor of high-performance coatings systems. It operates in
     > two segments. The Performance Coatings segment provides liquid
     > and powder coatings solutions to a fragmented and local customer
     > base. Its end markets include refinish and industrial. The Mobility
     > Coatings segment relates to the provision of coating technologies
     > to original equipment manufacturers of light and commercial
     > vehicles. The company operates in the geographic areas of North
     > America, EMEA countries, Asia-Pacific and Latin America.

Over the past 10 years, the medium-size company has grown sales and earnings at annualized rates of 1.6% and 27.3%, respectively. Lines are narrowing, somewhat up, and somewhat straight except for YOY sales declines in ’15, ’16, ’19, and ’20 along with EPS declines in ’16, ’17, ’20, and ’22. Ten- (Five-) year EPS R^2 is 0.66 (0.13), and Value Line gives an Earnings Predictability score of 40.

I think visual inspection just barely clears the barbed-wire fence. Sales growth is subbornly low while EPS—despite starting from a fractional base ($0.12 in ’14)—appears somewhat cyclical but certainly growing.

Over the past decade, PTPM trails peer and industry averages while increasing from 0.8% (’14) to 6.8% (’23) with a last-5-year mean of 6.1%. ROE also trails peer and industry averages despite increasing from 2.4% (’14) to 16.6% (’23) with a last-5-year mean of 15.6%. Debt-to-Capital is higher than peer and industry averages despite falling from 78.0% (’14) to 67.2% (’23) with a last-5-year mean of 71.7%.

Quick Ratio is 1.6 and Interest Coverage is 3.0 per M* who assigns a “Narrow” [quantitative] Economic Moat.

Value Line gives a B+ grade for Financial Strength and says the company is putting cash to good use:

     > Axalta closed the June quarter with $840 million in cash (up
     > from approximately $700 million at the end of 2023). The
     > company expanded its revolving credit facility to $800 million
     > in order to complete the CoverFlexx acquisition. The board
     > recently authorized a $700 million stock-repurchase program.
     > It may also use resources to refinance some of its debt.

With regard to sales growth:

My 2.0% per year forecast is below the range.

With regard to EPS growth:

My 12.0% per year forecast is below the long-term-estimate range (mean of four: 18.2%). Initial value is ’23 EPS of $1.21/share rather than 2024 Q2 EPS of $1.35 (annualized).

My Forecast High P/E is 28.0. Over the past decade, high P/E falls from 229 (’14) to 28.5 (’23) with a last-5-year mean of 37.7 and a last-5-year-mean average P/E of 30.3. I am below the range.

My Forecast Low P/E is 20.0. Over the past decade, low P/E falls from 168 (’14) to 20.7 (’23) with a last-5-year mean of 22.8. I am forecasting below the range.

My Low Stock Price Forecast (LSPF) of $24.20 is default based on initial value given above. This is 29.5% less than the previous closing price and 3.2% less than the 52-week low.

These inputs land AXTA in the HOLD zone with a U/D ratio of 2.4. Total Annualized Return (TAR) is 11.5%.

PAR (using Forecast Average—not High—P/E) of 8.2% is less than I seek from a medium-size company. If a healthy margin of safety (MOS) anchors the study, then I can proceed based on TAR instead.

To assess MOS, I usually start by comparing my inputs with those of Member Sentiment. I will skip because only one other study has been done over the past 90 days.

Value Line is more aggressive than me with average annual P/E of 30.0 (24.0) and high EPS of $2.30/share ($2.13).

My LSPF exceeds the pseudo-rule-of-thumb 20% discount to previous closing price.

MOS is robust because my inputs are near/below respective analyst/historical ranges.

With regard to valuation, PEG is 0.8 and 1.9 per Zacks and my projected P/E, respectively: fairly valued on average. Relative Value [(current P/E) / 5-year-mean average P/E] is somewhat low at 0.84.

I am concerned that sales may eventually be a drag on EPS growth, but the former is not material to this analysis.

Per U/D, AXTA is a BUY under $33/share. BI TAR criterion is met ~ $30/share given a forecast high price ~ $60 (no dividend).

A 90-day free trial to BetterInvestingĀ® may be secured here (also see link under “Pages” section at top right of this page).